Cargando…
Aromatase Inhibitors—Induced Musculoskeletal Disorders: Current Knowledge on Clinical and Molecular Aspects
Aromatase inhibitors (AIs) have radically changed the prognosis of hormone receptor positive breast cancer (BC) in post-menopausal women, and are a mainstay of the adjuvant therapy for BC after surgery in place of, or following, Tamoxifen. However, AIs aren’t side effect-free; frequent adverse event...
Autores principales: | Tenti, Sara, Correale, Pierpaolo, Cheleschi, Sara, Fioravanti, Antonella, Pirtoli, Luigi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7460580/ https://www.ncbi.nlm.nih.gov/pubmed/32781535 http://dx.doi.org/10.3390/ijms21165625 |
Ejemplares similares
-
MiR-214-3p, a novel possible therapeutic target for the pathogenesis of osteoarthritis
por: Fioravanti, Antonella, et al.
Publicado: (2021) -
Primary antiphospholipid syndrome during aromatase inhibitors therapy: A case report and review of the literature
por: Tenti, Sara, et al.
Publicado: (2019) -
New Trends in Injection-Based Therapy for Thumb-Base Osteoarthritis: Where Are We and where Are We Going?
por: Tenti, Sara, et al.
Publicado: (2021) -
Editorial: Year 2020: New Trends in Pharmacological Treatments for Osteoarthritis
por: Fioravanti, A., et al.
Publicado: (2022) -
Tocilizumab, Adipokines and Severe Complications of COVID-19
por: Fioravanti, Antonella, et al.
Publicado: (2020)